An analyst from Citi maintained Takeda Pharmaceutical (TYO: 4502) at 'neutral' with a price target of ¥4.3K from a prior price target of ¥4.6K. Prior to this rating, Takeda...
An analyst from UBS initiated coverage of Takeda Pharmaceutical (TYO: 4502) at 'neutral' with a price target of ¥4.5K. Prior to this rating, Takeda Pharmaceutical had 9 buy ratings, 8...
An analyst from Macquarie maintained Takeda Pharmaceutical (TYO: 4502) at 'outperform' with a price target of JPY4.8K. Prior to this rating, Takeda Pharmaceutical had 9 buy ratings, 9 hold...
An analyst from Jefferies maintained Takeda Pharmaceutical (TYO: 4502) at 'buy' with a price target of JPY5.2K from a prior price target of JPY5.3K. Prior to this rating, Takeda...
An analyst from Bernstein maintained Takeda Pharmaceutical (TYO: 4502) at 'market perform' with a price target of JPY4.2K. Prior to this rating, Takeda Pharmaceutical had 9 buy ratings, 10...
An analyst from Jefferies maintained Takeda Pharmaceutical (TYO: 4502) at 'buy' with a price target of JPY5.3K from a prior price target of JPY5.1K. Prior to this rating, Takeda...
An analyst from Jefferies maintained Takeda Pharmaceutical (TYO: 4502) at 'buy' with a price target of JPY5100.00. Prior to this rating, Takeda Pharmaceutical had 9 buy ratings, 11 hold...
An analyst from Citi maintained Takeda Pharmaceutical (TYO: 4502) at 'neutral' with a price target of JPY4600.00 from a prior price target of JPY4700.00. Prior to this rating, Takeda...
An analyst from Bernstein maintained Takeda Pharmaceutical (TYO: 4502) at 'market perform' with a price target of JPY4100.00. Prior to this rating, Takeda Pharmaceutical had 9 buy ratings,...
An analyst from Nomura/Instinet maintained Takeda Pharmaceutical (TYO: 4502) at 'buy' with a price target of JPY5800.00 from a prior price target of JPY5600.00. Prior to this rating,...
An analyst from Macquarie maintained Takeda Pharmaceutical (TYO: 4502) at 'outperform' with a price target of JPY4800.00 from a prior price target of JPY4900.00. Prior to this rating,...
An analyst from JPMorgan maintained Takeda Pharmaceutical (TYO: 4502) at 'neutral' with a price target of JPY4100.00 from a prior price target of JPY3900.00. Prior to this rating, Takeda...
An analyst from Jefferies maintained Takeda Pharmaceutical (TYO: 4502) at 'buy' with a price target of JPY5100.00 from a prior price target of JPY5000.00. Prior to this rating, Takeda...
An analyst from Morgan Stanley maintained Takeda Pharmaceutical (TYO: 4502) at 'equalweight' with a price target of JPY4200.00 from a prior price target of JPY4100.00. Prior to this...
An analyst from Citi maintained Takeda Pharmaceutical (TYO: 4502) at 'neutral' with a price target of JPY4700.00 from a prior price target of JPY4500.00. Prior to this rating, Takeda...
A Credit Suisse analyst maintained Takeda Pharmaceutical (TYO: 4502) at Neutral and a price target of $4100.00 from a prior price target of JPY4000.00. Prior to this rating, Takeda...
Investing.com – Japan equities were lower at the close on Wednesday, as losses in the Paper & Pulp, Railway & Bus and Real Estate sectors propelled shares lower. At the close in Tokyo, the...
By Stanley WhiteTOKYO, April 8 (Reuters) - Japanese stocks fell on Thursday, weighed by concerns over a spike in domestic coronavirus infections and the potential return of restrictions on...
By Stanley WhiteTOKYO, April 8 (Reuters) - Japanese stocks fell on Thursday as concerns about a spike in domestic coronavirus infections and a potential return of restrictions on economic...
TOKYO, April 6 (Reuters) - Japanese shares gave up early gains and slipped on Tuesday, as investors booked profits from recent rallies and treaded with caution as they await clues over the...
TOKYO, April 5 (Reuters) - Japanese shares rose on Monday as strong U.S. jobs data lifted optimism on economic recovery from the pandemic lows, prompting investors to buy index heavyweights...
Investing.com – Japan equities were lower at the close on Wednesday, as losses in the Paper & Pulp, Railway & Bus and Real Estate sectors propelled shares lower. At the close in Tokyo, the...
By Stanley White TOKYO, March 17 (Reuters) - Japanese stocks ended flat on Wednesday as profit-taking in the tech sector offset gains in healthcare, though the overall mood remained cautious...
By Stanley WhiteTOKYO, March 17 (Reuters) - Japanese stocks edged a tick higher on Wednesday as investors bought individual shares with bright earnings prospects, though the overall mood was...
TOKYO, March 8 (Reuters) - Japanese shares reversed course to end lower on Monday as some investors adjusted positions ahead of the end of the fiscal year, while concerns over rising U.S....
TOKYO, March 8 (Reuters) - Japanese shares rose on Monday as the central bank governor's remarks eased speculation that yields on government bonds would be allowed to rise, while optimism...
(Updates Atlantia )Feb 26 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Friday:** Italy's Atlantia ATL.MI said an offer by a consortium of...
TOKYO, Feb 18 (Reuters) - Japan's Nikkei inched up on Thursday, led by a sharp jump in Uniqlo-operator Fast Retailing, but gains were capped as investors weighed the sustainability of the...
TOKYO, Feb 8 (Reuters) - Japanese shares surged on Monday, with both Nikkei and Topix hitting 30-year highs, as strong corporate earnings lifted investor confidence for an economic recovery...
TOKYO, Feb 5 (Reuters) - Japanese shares ended more than 1% higher on Friday, following Wall Street's rally overnight, driven by upbeat earnings from domestic firms and expectations of a...
TOKYO, Feb 5 (Reuters) - Japanese shares rose on Friday, following Wall Street's rally overnight, as strong earning results of domestic firms and a large U.S. stimulus program boosted market...
By Stanley White TOKYO, Jan 26 (Reuters) - Japanese shares closed lower on Tuesday as worries about delays in distributing coronavirus vaccines, delay in U.S. stimulus package and jitters...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
